HRP20201179T4 - Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača - Google Patents
Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača Download PDFInfo
- Publication number
- HRP20201179T4 HRP20201179T4 HRP20201179TT HRP20201179T HRP20201179T4 HR P20201179 T4 HRP20201179 T4 HR P20201179T4 HR P20201179T T HRP20201179T T HR P20201179TT HR P20201179 T HRP20201179 T HR P20201179T HR P20201179 T4 HRP20201179 T4 HR P20201179T4
- Authority
- HR
- Croatia
- Prior art keywords
- fatty acids
- sustained release
- release formulations
- aqueous carriers
- triglycerides
- Prior art date
Links
- 239000008365 aqueous carrier Substances 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- -1 C12 fatty acids Chemical class 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Claims (1)
1. Proizvedeni gotovi pripravak za injekciju koji se uglavnom sastoji od suspenzije:
(i) farmaceutski prihvatljiv nosač koji sadrži jedan ili više triglicerida C6-C12 masnih kiselina; i
(ii) mikrosfere koje se uglavnom sastoje od poli(laktid-ko-glikolid) polimera koji ima dispergiran oko 5% (w/w) eksenatida kao aktivnog farmaceutskog sastojka i oko 2% (w/w) saharoze; pri čemu je omjer laktid:glikolid u polimeru oko 1:1
pri čemu se farmaceutski prihvatljiv nevodeni nosač sastoji od jednog ili više triglicerida C6-C12 masnih kiselina,
pri čemu trigliceridi sadrže 0 do 2 tež.% C6 masne kiseline, 50 do 65 tež.% C8 masne kiseline, 30 do 45 tež.% C10 masne kiseline i 0 do 2 tež.% C12 masne kiseline.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9438108P | 2008-09-04 | 2008-09-04 | |
PCT/US2009/056058 WO2010028257A1 (en) | 2008-09-04 | 2009-09-04 | Sustained release formulations using non-aqueous carriers |
EP09812292.2A EP2341905B2 (en) | 2008-09-04 | 2009-09-04 | Sustained release formulations using non-aqueous carriers |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20201179T1 HRP20201179T1 (hr) | 2020-11-13 |
HRP20201179T4 true HRP20201179T4 (hr) | 2024-02-16 |
Family
ID=41797509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201179TT HRP20201179T4 (hr) | 2008-09-04 | 2009-09-04 | Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača |
Country Status (24)
Country | Link |
---|---|
US (5) | US8895033B2 (hr) |
EP (2) | EP3685837A1 (hr) |
JP (2) | JP5744735B2 (hr) |
KR (1) | KR101760953B1 (hr) |
CN (2) | CN104248623B (hr) |
AU (1) | AU2009289529B2 (hr) |
BR (1) | BRPI0918904B8 (hr) |
CA (1) | CA2734525C (hr) |
CY (1) | CY1123410T1 (hr) |
DK (1) | DK2341905T4 (hr) |
EA (1) | EA020299B1 (hr) |
ES (1) | ES2809178T3 (hr) |
FI (1) | FI2341905T4 (hr) |
HR (1) | HRP20201179T4 (hr) |
HU (1) | HUE050125T2 (hr) |
IL (1) | IL211231A (hr) |
LT (1) | LT2341905T (hr) |
MX (1) | MX352189B (hr) |
NZ (1) | NZ604997A (hr) |
PL (1) | PL2341905T5 (hr) |
PT (1) | PT2341905T (hr) |
SG (1) | SG10201703039SA (hr) |
SI (1) | SI2341905T2 (hr) |
WO (1) | WO2010028257A1 (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145164B (zh) * | 2010-12-16 | 2013-02-27 | 深圳市健元医药科技有限公司 | 一种更加稳定的iapp类似物注射剂 |
WO2012170796A1 (en) * | 2011-06-09 | 2012-12-13 | Amylin Pharmaceuticals, Inc. | Gel compositions |
US20140220134A1 (en) * | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
CN104840415B (zh) * | 2014-02-19 | 2019-03-15 | 香港浸会大学 | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 |
US9656017B2 (en) | 2014-06-20 | 2017-05-23 | Howard E. Greene | Infusion delivery devices and methods |
EP3297653B1 (en) | 2015-05-22 | 2021-09-15 | The Board of Trustees of the Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with glp-1 antagonists |
CN108431028B (zh) * | 2015-10-27 | 2023-09-26 | 珀杜研究基金会 | 用于诱导性脂肪褐变的基于聚合物的治疗剂 |
WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
JP2019519478A (ja) | 2016-04-19 | 2019-07-11 | ユレカ・ソシエテ・ア・レスポンサビリテ・リミテUreka Sarl | ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法 |
CN110267648A (zh) | 2016-11-21 | 2019-09-20 | 艾格尔峰生物制药有限公司 | 毒蜥外泌肽(9-39)的缓冲制剂 |
BR112019012959A2 (pt) | 2017-01-09 | 2019-11-26 | Asarina Pharma Ab | suspensões injetáveis |
CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
KR101994456B1 (ko) * | 2017-03-15 | 2019-06-28 | 이건무 | 당 수액제 조성물 |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
CN113661006A (zh) | 2019-02-05 | 2021-11-16 | 林迪生物科学公司 | 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法 |
KR102045721B1 (ko) * | 2019-03-27 | 2019-11-18 | 주식회사 씨트리 | 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구 |
US20230210775A1 (en) * | 2019-09-19 | 2023-07-06 | Amw Gmbh | Extruded depot form for controlled active substance release |
GB202004115D0 (en) * | 2020-03-20 | 2020-05-06 | Invex Therapeutics Ltd | Modified release formulations and dosage regimens |
BR102021001712A2 (pt) * | 2021-01-29 | 2022-08-16 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da diabetes mellitus tipo 2 e processo |
JP2024513509A (ja) * | 2021-04-08 | 2024-03-25 | ティオンラボ・セラピューティクス | 徐放性脂質前駆製剤 |
WO2022226534A2 (en) * | 2021-04-23 | 2022-10-27 | Oakwood Laboratories, Llc | Microsphere formulations comprising multiple non-identical peptides and methods for making the same |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227520A (ja) * | 1985-04-02 | 1986-10-09 | Dai Ichi Seiyaku Co Ltd | マイクロスフエア |
US5439688A (en) | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
US5213810A (en) | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
US5122377A (en) * | 1990-11-19 | 1992-06-16 | A.H. Robins, Company, Incorporated | Oral delivery system for veterinary drugs |
DE4122217C2 (de) | 1991-07-04 | 1997-02-13 | Merz & Co Gmbh & Co | Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6913767B1 (en) * | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6245349B1 (en) * | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
ATE227980T1 (de) * | 1996-03-28 | 2002-12-15 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter freisetzung und deren herstellung |
US7276251B2 (en) * | 1997-04-01 | 2007-10-02 | Lg Life Sciences, Ltd., Inc. | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
AU3981097A (en) | 1996-08-21 | 1998-03-06 | Alkermes Controlled Therapeutics, Inc. | Controlled release microparticles with a hydrophobic material |
ES2425559T5 (es) | 1997-01-07 | 2018-02-02 | Amylin Pharmaceuticals, Llc | Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US6617321B2 (en) * | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
AU752225B2 (en) | 1998-07-17 | 2002-09-12 | Pacira Pharmaceuticals, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
ES2278589T3 (es) | 1999-01-14 | 2007-08-16 | Amylin Pharmaceuticals, Inc. | Excendinas destinadas a la inhibicion de glucagon. |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
DE10031744A1 (de) | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
US6967028B2 (en) * | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
DE60128261T3 (de) * | 2000-12-21 | 2016-06-30 | Alrise Biosystems Gmbh | Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln |
AUPR573001A0 (en) * | 2001-06-15 | 2001-07-12 | Glaxo Wellcome Australia Ltd | Lymphatic drug delivery system |
ATE478656T1 (de) * | 2001-06-22 | 2010-09-15 | Univ Johns Hopkins Med | Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
DE60335608D1 (de) * | 2002-02-27 | 2011-02-17 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7164005B2 (en) | 2002-10-17 | 2007-01-16 | Alkermes, Inc. | Microencapsulation and sustained release of biologically active polypeptides |
NZ539810A (en) * | 2002-11-06 | 2008-03-28 | Alza Corp | Controlled release injectable depot formulations |
WO2004050066A1 (en) * | 2002-11-27 | 2004-06-17 | The University Of Georgia Research Foundation, Inc. | Microspheres and related processes and pharmaceutical compositions |
IL155136A0 (en) * | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
JP5030292B2 (ja) * | 2004-04-15 | 2012-09-19 | アミリン・ファーマシューティカルズ,インコーポレイテッド | ポリマーを基にした持続放出性装置 |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
CN2763883Y (zh) * | 2004-12-30 | 2006-03-08 | 鸿富锦精密工业(深圳)有限公司 | 电脑壳体前板锁固装置 |
CA2609810C (en) * | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
NZ566763A (en) | 2005-08-19 | 2011-06-30 | Amylin Pharmaceuticals Inc | Exendin-4 for treating diabetes, obesity and reducing body weight |
WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
CA2626357A1 (en) * | 2005-10-20 | 2007-04-26 | Nastech Pharmaceutical Company Inc. | Intranasal administration of rapid acting insulin |
WO2007067964A2 (en) * | 2005-12-08 | 2007-06-14 | Nastech Pharmaceutical Company Inc. | Mucosal delivery of stabilized formulations of exendin |
MX2008015107A (es) | 2006-05-26 | 2008-12-09 | Amylin Pharmaceuticals Inc | Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva. |
CA2659330A1 (en) * | 2006-07-31 | 2008-02-07 | Neurosystec Corporation | Nanoparticle drug formulations |
US7682356B2 (en) | 2006-08-09 | 2010-03-23 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
KR20090094811A (ko) | 2006-10-05 | 2009-09-08 | 파나세아 바이오테크 리미티드 | 새로운 형태의 주입형 데포조성물 및 이를 조제하기 위한 방법 |
CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
EP2011452B1 (fr) | 2007-07-06 | 2014-04-30 | S.B.I.R. Sprl | Préparation injectable pour la réalisation d'un implant musculaire |
EP2303313B1 (en) | 2008-05-21 | 2015-10-28 | Amylin Pharmaceuticals, LLC | Exendins to lower cholestrol and triglycerides |
-
2009
- 2009-09-04 US US13/060,225 patent/US8895033B2/en active Active
- 2009-09-04 SG SG10201703039SA patent/SG10201703039SA/en unknown
- 2009-09-04 CA CA2734525A patent/CA2734525C/en active Active
- 2009-09-04 PL PL09812292.2T patent/PL2341905T5/pl unknown
- 2009-09-04 JP JP2011526233A patent/JP5744735B2/ja active Active
- 2009-09-04 DK DK09812292.2T patent/DK2341905T4/da active
- 2009-09-04 SI SI200932079T patent/SI2341905T2/sl unknown
- 2009-09-04 EP EP20163108.2A patent/EP3685837A1/en active Pending
- 2009-09-04 ES ES09812292T patent/ES2809178T3/es active Active
- 2009-09-04 KR KR1020117007223A patent/KR101760953B1/ko active IP Right Grant
- 2009-09-04 LT LTEP09812292.2T patent/LT2341905T/lt unknown
- 2009-09-04 EP EP09812292.2A patent/EP2341905B2/en active Active
- 2009-09-04 PT PT98122922T patent/PT2341905T/pt unknown
- 2009-09-04 NZ NZ604997A patent/NZ604997A/en unknown
- 2009-09-04 CN CN201410373411.5A patent/CN104248623B/zh active Active
- 2009-09-04 HR HRP20201179TT patent/HRP20201179T4/hr unknown
- 2009-09-04 AU AU2009289529A patent/AU2009289529B2/en active Active
- 2009-09-04 BR BRPI0918904A patent/BRPI0918904B8/pt active IP Right Grant
- 2009-09-04 MX MX2011002398A patent/MX352189B/es active IP Right Grant
- 2009-09-04 CN CN200980134725.7A patent/CN102164597B/zh active Active
- 2009-09-04 HU HUE09812292A patent/HUE050125T2/hu unknown
- 2009-09-04 EA EA201170413A patent/EA020299B1/ru not_active IP Right Cessation
- 2009-09-04 FI FIEP09812292.2T patent/FI2341905T4/fi active
- 2009-09-04 WO PCT/US2009/056058 patent/WO2010028257A1/en active Application Filing
-
2011
- 2011-02-15 IL IL211231A patent/IL211231A/en active IP Right Grant
-
2014
- 2014-10-27 US US14/524,521 patent/US20150056285A1/en not_active Abandoned
-
2015
- 2015-02-05 JP JP2015021556A patent/JP6051243B2/ja active Active
-
2016
- 2016-08-11 US US15/234,021 patent/US20160346357A1/en not_active Abandoned
-
2018
- 2018-02-16 US US15/898,381 patent/US20180271946A1/en not_active Abandoned
-
2020
- 2020-05-13 US US15/931,123 patent/US20200405815A1/en not_active Abandoned
- 2020-07-27 CY CY20201100689T patent/CY1123410T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201179T4 (hr) | Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača | |
ES2617683T3 (es) | Composiciones oftálmicas basadas en ácidos grasos Omega-3 y Omega-6 poliinsaturados | |
HRP20221208T1 (hr) | Depot sustav koji sadrži glatiramer acetat | |
PE20071139A1 (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
EP2322146A3 (en) | Microcapsule formulations comprising two pharmaceutically active ingredients | |
CY1112333T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα | |
JP2013508296A5 (hr) | ||
NZ600721A (en) | Capsule formulation | |
CO6220926A2 (es) | Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid) | |
JP2013516403A5 (hr) | ||
ES2281313T1 (es) | Composiciones farmaceuticas que comprenden lercanidipino. | |
RU2011148140A (ru) | Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления | |
AR059829A1 (es) | Sistemas estables de nanocapsulas para la administracion de moleculas activas | |
AR077155A1 (es) | Nanodispersion, nanoparticulas y solucion | |
RU2019126797A (ru) | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора | |
BR112012026223A2 (pt) | formulação adequada para o uso em ração animal, uso, e ração para animais. | |
BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
HRP20201923T1 (hr) | Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije | |
NZ603497A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
WO2014022761A3 (en) | Method of protecting active ingredient from degradation during pelleting | |
CO6382109A2 (es) | Formulación de depósito de octreotida con niveles de exposición constantemente altos | |
RU2018105067A (ru) | Фармацевтические композиции, содержащие целекоксиб и трамадол | |
JP2014503479A5 (ja) | アリピプラゾール組成物 | |
AR076305A1 (es) | Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo |